Compare ALMR & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALMR | PBH |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 2026 | 2004 |
| Metric | ALMR | PBH |
|---|---|---|
| Price | $28.64 | $49.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $37.00 | ★ $66.20 |
| AVG Volume (30 Days) | ★ 674.6K | 533.9K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.14 |
| Revenue | N/A | ★ $975,777,000.00 |
| Revenue This Year | $64.80 | $17.88 |
| Revenue Next Year | $37.27 | $6.80 |
| P/E Ratio | ★ N/A | $44.08 |
| Revenue Growth | N/A | ★ 36.77 |
| 52 Week Low | $21.58 | $41.77 |
| 52 Week High | $39.61 | $71.07 |
| Indicator | ALMR | PBH |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 56.12 |
| Support Level | $23.87 | $47.23 |
| Resistance Level | $29.06 | $50.26 |
| Average True Range (ATR) | 2.38 | 2.13 |
| MACD | -0.06 | 0.43 |
| Stochastic Oscillator | 47.77 | 68.96 |
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.